Metrology Research Centre, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Integrated Nanotherapeutics, Burnaby, BC, V5G 4X4, Canada.
Sci Rep. 2022 Oct 27;12(1):18071. doi: 10.1038/s41598-022-23013-2.
Lipid based nanocarriers are one of the most effective drug delivery systems that is evident from the recent COVID-19 mRNA vaccines. The main objective of this study was to evaluate toxicity of six lipid based formulations with three surface charges-anionic, neutral or cationic, to establish certified reference materials (CRMs) for liposomes and siRNA loaded lipid nanoparticles (LNP-siRNA). Cytotoxicity was assessed by a proliferation assay in adherent and non-adherent cell lines. High concentration of three LNP-siRNAs did not affect viability of suspension cells and LNP-siRNAs were non-toxic to adherent cells at conventionally used concentration. Systematic evaluation using multiple vials and repeated test runs of three liposomes and three LNP-siRNA formulations showed no toxicity in HL60 and A549 cells up to 128 and 16 µg/mL, respectively. Extended treatment and low concentration of LNPs did not affect the viability of suspension cells and adherent cells at 96 h. Interestingly, 80% of A549 and HL60 cells in 3D conditions were viable when treated with cationic LNP-siRNA for 48 h. Taken together, anionic, cationic and neutral lipid formulations were non-toxic to cells and may be explored further in order to develop them as drug carriers.
基于脂质的纳米载体是最有效的药物递送系统之一,这一点从最近的 COVID-19 mRNA 疫苗中可见一斑。本研究的主要目的是评估六种带三种表面电荷(阴离子、中性或阳离子)的基于脂质的制剂的毒性,为脂质体和负载 siRNA 的脂质纳米颗粒 (LNP-siRNA) 建立认证参考材料 (CRM)。通过贴壁和非贴壁细胞系的增殖测定评估细胞毒性。高浓度的三种 LNP-siRNA 不会影响悬浮细胞的活力,并且在常规使用浓度下,LNP-siRNA 对贴壁细胞无毒。使用多个小瓶和三种脂质体和三种 LNP-siRNA 制剂的重复测试运行进行系统评估表明,HL60 和 A549 细胞中三种脂质体的浓度高达 128 和 16μg/mL 时无毒。延长处理时间和低浓度的 LNPs 在 96 小时内不会影响悬浮细胞和贴壁细胞的活力。有趣的是,当用阳离子 LNP-siRNA 处理 48 小时时,80%的 A549 和 HL60 细胞在 3D 条件下仍然存活。总之,阴离子、阳离子和中性脂质制剂对细胞无毒,可进一步探索用于开发它们作为药物载体。